{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T16:52:38Z","timestamp":1774630358462,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Drug-induced long QT interval syndrome (LQTS) is a risk for Torsade de Pointes (TdP) arrhythmia. The purpose was to investigate patients diagnosed with TdP in relation to dispensed risk drugs, the presence of comorbidities, and sex-differences.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>All patients with a first episode of a registered TdP diagnosis in the National Patient Register between 2006 and 2018 were included in this register-based cohort study. Comorbidities within five years and medications dispensed within 90\u00a0days prior to TdP diagnosis were retrieved. Drugs were classified for their risk to cause TdP (\u201crisk drugs\u201d) using two different Clinical Decision Support Systems (CredibleMeds and Janusmed).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort consisted of 762 patients (50% females) with TdP, median age 72\u00a0years. A majority (59%) were dispensed at least one risk drug and 338 patients (44%) had at least one risk diagnosis for TdP. Concomitant use of several risk drugs was common. Prior to TdP, 558 patients (73%) had at least one risk diagnosis and\/or were dispensed at least one risk drug. More females than males used antidepressants (26% vs 12%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01) although the total use of risk drugs were similar in females compared to males. More males than females had risk diagnoses for TdP (53% vs. 36%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>A majority of patients with TdP had been dispensed risk drugs and\/or had risk diagnoses. Sex-differences in dispensed drugs and risk diagnoses were identified. Prescription drugs, underlying risk diagnoses and sex should be incorporated into the risk assessment for TdP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00228-025-03990-9","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T08:43:59Z","timestamp":1768812239000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prescribed drugs and comorbidities as risk factors for Torsades de Pointes arrhythmia: a Swedish population-based cohort study"],"prefix":"10.1007","volume":"82","author":[{"given":"Marine L.","family":"Andersson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Fastbom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bengt","family":"Danielsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marja-Liisa","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karolina","family":"Nowinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"issue":"15","key":"3990_CR1","doi-asserted-by":"publisher","first-page":"e214","DOI":"10.1161\/CIR.0000000000000905","volume":"142","author":"JE Tisdale","year":"2020","unstructured":"Tisdale JE, Chung MK, Campbell KB, Hammadah M, Joglar JA, Leclerc J et al (2020) Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation 142(15):e214\u2013ee33","journal-title":"Circulation"},{"issue":"7","key":"3990_CR2","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1161\/CIRCULATIONAHA.123.063917","volume":"150","author":"ZR Al Sayed","year":"2024","unstructured":"Al Sayed ZR, Pereira C, Le Borgne R, Viaris de Lesegno C, Jouve C, Penard E et al (2024) CAVIN1-mediated hERG dynamics: a novel mechanism underlying the Interindividual variability in drug-induced long QT. Circulation 150(7):563\u2013576","journal-title":"Circulation"},{"key":"3990_CR3","unstructured":"QTdrugs List [Internet]. AZCERT, Inc. 1822 Innovation Park Dr., Oro Valley, AZ 85755v. [cited 2020-12-01]"},{"issue":"3","key":"3990_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00228-017-2391-3","volume":"74","author":"Y Bottiger","year":"2018","unstructured":"Bottiger Y, Laine K, Korhonen T, Lahdesmaki J, Shemeikka T, Julander M et al (2018) Development and pilot testing of PHARAO-a decision support system for pharmacological risk assessment in the elderly. Eur J Clin Pharmacol 74(3):365\u2013371","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3990_CR5","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1111\/bcp.12829","volume":"81","author":"B Danielsson","year":"2016","unstructured":"Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J (2016) Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol 81(4):773\u2013783","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"3990_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-034560","volume":"10","author":"B Danielsson","year":"2020","unstructured":"Danielsson B, Collin J, Nyman A, Bergendal A, Borg N, State M et al (2020) Drug use and torsades de pointes cardiac arrhythmias in Sweden: a nationwide register-based cohort study. BMJ Open 10(3):e034560","journal-title":"BMJ Open"},{"key":"3990_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-450","volume":"11","author":"JF Ludvigsson","year":"2011","unstructured":"Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C et al (2011) External review and validation of the Swedish national inpatient register. BMC Public Health 11:450","journal-title":"BMC Public Health"},{"issue":"7","key":"3990_CR8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/pds.1294","volume":"16","author":"B Wettermark","year":"2007","unstructured":"Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U et al (2007) The new Swedish prescribed drug register--opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 16(7):726\u2013735","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"3990_CR9","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s10654-017-0316-1","volume":"32","author":"HL Brooke","year":"2017","unstructured":"Brooke HL, Talback M, Hornblad J, Johansson LA, Ludvigsson JF, Druid H et al (2017) The Swedish cause of death register. Eur J Epidemiol 32(9):765\u2013773","journal-title":"Eur J Epidemiol"},{"key":"3990_CR10","doi-asserted-by":"crossref","unstructured":"Hammar T, Jonsen E, Bjorneld O, Askfors Y, Andersson ML, Lincke A (2024) Potential adverse drug events identified with decision support algorithms from Janusmed risk profile-a retrospective population-based study in a Swedish region. Pharmacy 12(6)","DOI":"10.3390\/pharmacy12060168"},{"issue":"1","key":"3990_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12012-017-9416-0","volume":"18","author":"G Frommeyer","year":"2018","unstructured":"Frommeyer G, Fischer C, Ellermann C, Dechering DG, Kochhauser S, Lange PS et al (2018) Additive Proarrhythmic effect of combined treatment with QT-prolonging agents. Cardiovasc Toxicol 18(1):84\u201390","journal-title":"Cardiovasc Toxicol"},{"issue":"4","key":"3990_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1097\/01.md.0000085057.63483.9b","volume":"82","author":"D Zeltser","year":"2003","unstructured":"Zeltser D, Halkin A, Prokhorov V, Heller K, Viskin S, de Pointes T (2003) Due to noncardiac drugs. Most patients have easily identifiable risk factors. Medicine 82(4):282\u2013290","journal-title":"Medicine"},{"issue":"1","key":"3990_CR13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1093\/europace\/eut214","volume":"16","author":"G Sarganas","year":"2014","unstructured":"Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W (2014) Epidemiology of symptomatic drug-induced long QT syndrome and torsade de pointes in Germany. Europace 16(1):101\u2013108","journal-title":"Europace"},{"issue":"2","key":"3990_CR14","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/cpt.2813","volume":"113","author":"MI Then","year":"2023","unstructured":"Then MI, Tumena T, Sledziewska A, Gassmann KG, Maas R, Fromm MF (2023) Development in prescriptions of contraindicated and potentially harmful QT interval-prolonging drugs in a large geriatric inpatient cohort from 2011 to 2021. Clin Pharmacol Ther 113(2):435\u2013445","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"3990_CR15","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1177\/2045125317721662","volume":"7","author":"AD Meid","year":"2017","unstructured":"Meid AD, Bighelli I, Machler S, Mikus G, Carra G, Castellazzi M et al (2017) Combinations of QTc-prolonging drugs: towards disentangling pharmacokinetic and pharmacodynamic effects in their potentially additive nature. Ther Adv Psychopharmacol 7(12):251\u2013264","journal-title":"Ther Adv Psychopharmacol"},{"issue":"37","key":"3990_CR16","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1093\/eurheartj\/ehz228","volume":"40","author":"PE Weeke","year":"2019","unstructured":"Weeke PE, Kellemann JS, Jespersen CB, Theilade J, Kanters JK, Hansen MS et al (2019) Long-term proarrhythmic pharmacotherapy among patients with congenital long QT syndrome and risk of arrhythmia and mortality. Eur Heart J 40(37):3110\u20133117","journal-title":"Eur Heart J"},{"issue":"5","key":"3990_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.jacep.2022.02.017","volume":"8","author":"AD Krahn","year":"2022","unstructured":"Krahn AD, Laksman Z, Sy RW, Postema PG, Ackerman MJ, Wilde AAM et al (2022) Congenital long QT syndrome. JACC Clin Electrophysiol 8(5):687\u2013706","journal-title":"JACC Clin Electrophysiol"},{"issue":"38","key":"3990_CR18","doi-asserted-by":"publisher","first-page":"3915","DOI":"10.1093\/eurheartj\/ehab362","volume":"42","author":"JE Salem","year":"2021","unstructured":"Salem JE, Nguyen LS, Moslehi JJ, Ederhy S, Lebrun-Vignes B, Roden DM et al (2021) Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. Eur Heart J 42(38):3915\u20133928","journal-title":"Eur Heart J"},{"issue":"1","key":"3990_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s40360-017-0181-2","volume":"18","author":"Q Khan","year":"2017","unstructured":"Khan Q, Ismail M, Khan S (2017) Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study. BMC Pharmacol Toxicol 18(1):75","journal-title":"BMC Pharmacol Toxicol"},{"issue":"4","key":"3990_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40266-023-01021-9","volume":"40","author":"L Petersson","year":"2023","unstructured":"Petersson L, Schorgenhofer C, Askfors Y, Justad H, Dahl ML, Andersson ML (2023) Pharmacological risk assessment among older patients with polypharmacy using the clinical decision support system Janusmed risk profile: a cross-sectional register study. Drugs Aging 40(4):369\u2013376","journal-title":"Drugs Aging"},{"issue":"1","key":"3990_CR21","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1055\/s-0041-1724043","volume":"12","author":"KE Trinkley","year":"2021","unstructured":"Trinkley KE, Pell JM, Martinez DD, Maude NR, Hale G, Rosenberg MA (2021) Assessing prescriber behavior with a clinical decision support tool to prevent drug-induced long QT syndrome. Appl Clin Inform 12(1):190\u2013197","journal-title":"Appl Clin Inform"},{"issue":"6","key":"3990_CR22","doi-asserted-by":"publisher","first-page":"e1010","DOI":"10.1097\/PTS.0000000000000996","volume":"18","author":"T Gallo","year":"2022","unstructured":"Gallo T, Heise CW, Woosley RL, Tisdale JE, Antonescu CC, Gephart SM et al (2022) Clinician satisfaction with advanced clinical decision support to reduce the risk of Torsades de Pointes. J Patient Saf 18(6):e1010\u2013e10e3","journal-title":"J Patient Saf"},{"issue":"4","key":"3990_CR23","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1111\/bcp.15580","volume":"89","author":"KM Muylle","year":"2023","unstructured":"Muylle KM, van Laere S, Pannone L, Coenen S, de Asmundis C, Dupont AG et al (2023) Added value of patient- and drug-related factors to stratify drug-drug interaction alerts for risk of QT prolongation: development and validation of a risk prediction model. Br J Clin Pharmacol 89(4):1374\u20131385","journal-title":"Br J Clin Pharmacol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03990-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03990-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03990-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T15:06:29Z","timestamp":1771859189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03990-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3990"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03990-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Swedish Ethical Review Authority, registration number 2020\u201302643. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Consent to Participate declarations: not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"57"}}